Literature DB >> 23011874

Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis?

Mustafa R Bashir1, Rajan T Gupta, Matthew S Davenport, Brian C Allen, Tracy A Jaffe, Lisa M Ho, Daniel T Boll, Elmar M Merkle.   

Abstract

PURPOSE: To evaluate the value of hepatobiliary phase imaging for detection and characterization of hepatocellular carcinoma (HCC) in liver MRI with Gd-EOB-DTPA, in a North American population.
MATERIALS AND METHODS: One hundred MRI examinations performed with the intravenous injection of Gd-EOB-DTPA in patients with cirrhosis were reviewed retrospectively. Nodules were classified as HCC (n = 70), indeterminate (n = 33), or benign (n = 22). Five readers independently reviewed each examination with and without hepatobiliary phase images (HBP). Lesion conspicuity scores were compared between the two readings. Lesion detection, confidence scores, and receiver operating characteristic (ROC) analysis were compared.
RESULTS: Lesion detection was slightly improved for all lesion types with the inclusion of the HBP, and was substantially higher for small HCCs (96.0% versus 85.3%). Mean confidence scores for the diagnosis of HCC increased for HCCs overall and each size category (P < 0.001). Diagnostic performance improved with the addition of the HBP (aggregate AROC 87.7% versus 80.0%, P < 0.01), and sensitivity for characterization improved (90.9% versus 78.3%, P < 0.01) while specificity was unchanged.
CONCLUSION: Hepatobiliary phase imaging may improve small lesion detection (<1 cm) and characterization of lesions in general, in MRI of the cirrhotic liver with Gd-EOB-DTPA.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23011874     DOI: 10.1002/jmri.23818

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  34 in total

1.  Diagnostic Accuracy of Preoperative Gadoxetic Acid-enhanced 3-T MR Imaging for Malignant Liver Lesions by Using Ex Vivo MR Imaging-matched Pathologic Findings as the Reference Standard.

Authors:  Eduardo A C Costa; Guilherme M Cunha; Emmanuil Smorodinsky; Irene Cruite; An Tang; Robert M Marks; Lisa Clark; Tanya Wolfson; Anthony Gamst; Jason K Sicklick; Alan Hemming; Michael R Peterson; Michael S Middleton; Claude B Sirlin
Journal:  Radiology       Date:  2015-04-15       Impact factor: 11.105

2.  Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients.

Authors:  Sith Phongkitkarun; Kuruwin Limsamutpetch; Penampai Tannaphai; Janjira Jatchavala
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

Review 3.  Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents.

Authors:  Anum Aslam; Amita Kamath; Bradley Spieler; Mark Maschiocchi; Carl F Sabottke; Victoria Chernyak; Sara C Lewis
Journal:  Abdom Radiol (NY)       Date:  2021-04-15

4.  The challenges of novel contrast agents for the imaging diagnosis of hepatocellular carcinoma.

Authors:  Carmen Ayuso; Jordi Bruix
Journal:  Hepatol Int       Date:  2013-12-28       Impact factor: 6.047

5.  Influence of Gd-EOB-DTPA on T1 dependence of the proton density fat fraction using magnetic resonance spectroscopy.

Authors:  Tatsuya Hayashi; Kei Fukuzawa; Hiroshi Kondo; Hiroshi Onodera; Rie Tojo; Shimpei Yano; Tosiaki Miyati; Jun'ichi Kotoku; Takahide Okamoto; Keiko Toyoda; Hiroshi Oba
Journal:  Radiol Phys Technol       Date:  2018-06-01

Review 6.  Benign solid tumors of the liver: management in the modern era.

Authors:  Georgios Antonios Margonis; Aslam Ejaz; Gaya Spolverato; Neda Rastegar; Robert Anders; Ihab R Kamel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2015-01-06       Impact factor: 3.452

Review 7.  Radiotherapeutic options for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Dong Soo Lee; Jinsil Seong
Journal:  Liver Cancer       Date:  2014-03       Impact factor: 11.740

Review 8.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

9.  Peritoneal and pleural fluids may appear hyperintense on hepatobiliary phase using hepatobiliary MR contrast agents.

Authors:  Maria Ciolina; Michele Di Martino; Onorina Bruno; Romain Pommier; Valérie Vilgrain; Maxime Ronot
Journal:  Eur Radiol       Date:  2018-01-26       Impact factor: 5.315

10.  Comparison of hepatocellular carcinoma conspicuity on hepatobiliary phase images with gadoxetate disodium vs. delayed phase images with extracellular cellular contrast agent.

Authors:  So Yeon Kim; En-Haw Wu; Seong Ho Park; Z Jane Wang; Thomas A Hope; Judy Yee; Li-Qin Zhao; Wei-Chou Chang; Benjamin M Yeh
Journal:  Abdom Radiol (NY)       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.